Down 44% in a year while the S&P 500 rose 12%; up 246% over three years.
HIMS's Quality Score fell 2 points on Tue, Nov 10, to -5. Its price is now lower than two years ago.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2025 high | Down 67% |
| Its score | Down:Lowest Quality Score since Nov 2022 |
| Latest filing | 8-K, Nov 9 |
ReportLast night: sales of $890.4M; a loss of $0.14 a share. Lowered its outlook for the year. Past reports ›
YesterdayHims & Hers Health reported $890.4 million of quarterly revenue and a loss of $0.14 a share
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
HIMS closed +8.1% that day.
After its last 4 reports it closed -8.8% on average, higher 0 of 4 times.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. HIMS scores -5 today, against a median of 1 over its last 20 recorded sessions.
HIMS is #5 of 6 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 2 | ||
| 3 | ||
| 5 | ||
| Open for its score |
Expected to report Mon Mar 1, after the close (in 111 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $890.4M, 49% more than a year ago; a loss of $0.14 a share, from a profit of $0.06.
HIMS's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $3.13B to $3.15B |
Sales grew 74% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 8.1% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -3.6% | -16.6% | not yet |
| Aug 10, 2026 | -6.5% | -4.0% | -9.9% |
| May 11, 2026 | -13.5% | -14.1% | -23.5% |
Sales grew every year from 2019 to 2025, to $2.3B. It made a profit in two of the seven years.
RSI 29.5, MACD below signal, below both averages. Not scored.
One insider bought $1.2M across 1 filing in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: HIMS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
“While we believe there are currently no direct competitors that offer the full suite of solutions and direct-to-consumer touch points as we do, there are several companies that offer components of telehealth or address conditions that compete with our solutions.”
HIMS scores -5 today, which Breakaway calls Poor. It is #5 of 6 in Services-Offices & Clinics of Doctors of Medicine by Quality Score, with 1 of 14 chart checks firing. Down 44% in a year while the S&P 500 rose 12%; up 246% over three years. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
HIMS scores -5 today, which Breakaway calls Poor (below zero). That is #5 of 6 in Services-Offices & Clinics of Doctors of Medicine by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind HIMS's -5.
One insider bought $1.2M across 1 filing in the last 6 months. No open-market sales on record. The newest is David B. Wells, Director, who bought $1.2M on May 26.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.